Sep 25, 2025 | Case Study, Case Study Forecasting
A multinational pharmaceutical firm asked Ozmosi to provide forecasts to assess the market impact of delays in delivering new formulation and packaging for an existing product. A planned reformulation seen as necessary to preserving market share had been delayed for...
Sep 25, 2025 | Business, Chronic Disease, Diabetes, Disease Area Trends
For years, Eli Lilly’s main contributions to the Diabetes market were their insulins: fast-acting analog Humalog® and human insulin Humalin and two premix offerings in analog Humalog® Mix 50/50 and human premix Humalin 75/25. Despite a legacy category, this portfolio...
Sep 25, 2025 | Chronic Disease, Diabetes, Disease Area Trends
Novo Nordisk remains a top player in the Diabetes market with blockbuster insulins NovoLog® and Levemir® which brought in a combined almost $3.5 billion in 20166, Victoza® a GLP-1 that brought in $2.1 billion in 20166, and recently launched Basal insulin/GLP-1...
Sep 25, 2025 | Chronic Disease, Diabetes, Disease Area Trends
Diabetes is one of the most prevalent diseases in the U.S., afflicting over 29 million people across Type 1 and Type 2 patients, according to the CDC1 and represents over a $50 billion dollar industry2. Pharmaceutical companies are constantly racing to create the next...
Sep 25, 2025 | Cancer, Industry Trends
LUNG CANCER SCREENING UPDATE: As of February 5, 2015, effective immediately, Medicare will cover lung cancer screening by low-dose CT. ORIGINAL POST – Dec. 1, 2014 The Centers for Medicare & Medicaid Services (CMS) recently issued a proposal for Medicare to cover...
